Transaction DateRecipientSharesTypePriceValue
25th February 2020Brent Atwood1,650,000Sale back to the issuer$0.00$1,650.00
25th February 2020Brent Atwood2,148,604Sale back to the issuer$0.00$2,148.60
25th February 2020Brent Atwood6,000,000Sale back to the issuer$0.00$6,000.00
25th February 2020Brent Atwood250,000Sale back to the issuer$0.00$250.00
25th February 2020Brent Atwood2,000,000Sale back to the issuer$0.00$4,000.00
25th February 2020Brent Atwood7,447,200Sale back to the issuer$0.00$7,447.20
25th February 2020Brent Atwood2,282,400Sale back to the issuer$0.00$4,564.80
25th February 2020Brent Atwood2,750,000Sale back to the issuer$0.00$2,750.00
25th February 2020Brent Atwood6,927,500Sale back to the issuer$0.00$6,927.50
25th February 2020Brent Atwood50,000Sale back to the issuer$0.00$50.00
Angio Soma
Angio Soma logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


AngioSoma, Inc. engages in the manufacture and marketing of pharmaceuticals and nutraceutical supplements. It also develops Liprostin for the treatment of peripheral artery disease. The company was founded by David P. Summers on April 29, 2016.


Ticker: SOAN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1502152
Employees:
Exchange: US OTC
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals